Equities Analysts Issue Forecasts for bluebird bio, Inc.’s Q3 2017 Earnings (BLUE)

bluebird bio, Inc. (NASDAQ:BLUE) – Stock analysts at Jefferies Group issued their Q3 2017 EPS estimates for shares of bluebird bio in a report issued on Wednesday. Jefferies Group analyst B. Amin expects that the biotechnology company will post earnings of ($1.75) per share for the quarter. Jefferies Group currently has a “Hold” rating and a $126.00 target price on the stock. Jefferies Group also issued estimates for bluebird bio’s Q4 2017 earnings at ($1.84) EPS, FY2017 earnings at ($7.01) EPS, FY2018 earnings at ($7.28) EPS, FY2019 earnings at ($7.05) EPS, FY2020 earnings at ($4.21) EPS and FY2021 earnings at $4.34 EPS.

Several other brokerages have also issued reports on BLUE. Cantor Fitzgerald reiterated a “sell” rating and set a $39.00 target price on shares of bluebird bio in a research report on Thursday, September 28th. Leerink Swann reiterated an “outperform” rating and set a $120.00 target price on shares of bluebird bio in a research report on Saturday, September 30th. Morgan Stanley lowered shares of bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 target price for the company. in a research report on Monday, October 2nd. Wells Fargo & Company reiterated an “outperform” rating and set a $158.00 target price (up from $134.00) on shares of bluebird bio in a research report on Tuesday, September 5th. Finally, Maxim Group reiterated a “buy” rating and set a $170.00 target price (up from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $118.81.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/10/15/equities-analysts-issue-forecasts-for-bluebird-bio-inc-s-q3-2017-earnings-blue.html.

Shares of bluebird bio (NASDAQ BLUE) opened at 131.70 on Friday. bluebird bio has a one year low of $37.05 and a one year high of $143.50. The company’s market cap is $6.00 billion. The stock’s 50 day moving average is $127.32 and its 200-day moving average is $102.33.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by ($0.07). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. During the same period last year, the company posted ($1.59) EPS. The business’s revenue was up 977.4% on a year-over-year basis.

In related news, insider Philip D. Gregory sold 750 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $99.00, for a total transaction of $74,250.00. Following the completion of the sale, the insider now directly owns 31,234 shares in the company, valued at approximately $3,092,166. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Davidson sold 4,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $131.31, for a total transaction of $525,240.00. The disclosure for this sale can be found here. Insiders have sold a total of 131,779 shares of company stock valued at $16,038,514 over the last quarter. 3.90% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. FMR LLC raised its holdings in bluebird bio by 9.6% during the 2nd quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after buying an additional 587,236 shares during the last quarter. Capital Research Global Investors raised its holdings in bluebird bio by 9.9% during the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares during the last quarter. Baillie Gifford & Co. raised its holdings in bluebird bio by 3.8% during the 2nd quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after buying an additional 196,025 shares during the last quarter. Vanguard Group Inc. raised its holdings in bluebird bio by 10.7% during the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after buying an additional 343,856 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in bluebird bio by 4.3% during the 2nd quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after buying an additional 138,141 shares during the last quarter.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply